NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ProKidney Corp. (PROK) Stock Analysis

ProKidney Corp. (PROK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PROK

$1.44

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PROK with… →

PROK Key Statistics

As of Oct 21, 2026
Trading
Open
$1.44
Previous Close
$1.44
Day's Range
1.44–1.49
52-Week Range
1.30–3.48
Volume
601.29K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$574.82M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
702.72
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.55
Financials (FY)
Revenue (FY)
$893.00K+1,075.00%
Net Income (FY)
−$68.99M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
208.93M
1-Year Return
−56.36%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.32M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PROK closed at $1.44, −56.36% over 1 year.

ProKidney Corp. (PROK) has a market capitalization of $574.82M.

In fiscal 2025, PROK reported revenue of $893.00K.

PROK Stock Return by Calendar Year

ProKidney Corp. (PROK) return since Jun 2021: what $10,000 became

1 year
$10,000 $4,364
−56.36%
5 years
$10,000 $1,465
−85.35%
Since Jun 2021
$10,000 $1,424
−85.76%

If you had invested $10,000 in ProKidney Corp. (PROK) at the close on June 30, 2021, the earliest close on record here, it would have been worth $1,424 at the close on October 21, 2026: −85.76% in total, −30.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.71%
2025+32.54%
2024−5.06%
2023−74.05%
2022−30.71%
2021 (partial year)−2.08%

As of October 21, 2026.

PROK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$893.00K−$68.99M−7,725.2%
2024$76.00K−$61.19M−80,507.9%
2023$0.00−$35.47M—
2022$0.00−$108.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$893.00K—−$165.01M−$68.99M−7,725.2%
2024$76.00K—−$183.68M−$61.19M−80,507.9%
2023$0.00—−$151.52M−$35.47M—
2022$0.00—−$153.01M−$108.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PROK Valuation vs Biotechnology Median

Median of 608 stocks
MetricPROKBiotechnology medianvs median
P/S ratio702.7213.3052.8x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ProKidney Corp. (PROK) carries a market capitalisation of $574.82M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 231 employees.

PROK last closed at $1.44 on October 21, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $1.30 to $3.48. The latest close sits 10.77% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $893.00K. Against the prior fiscal year total of $76.00K, that is a change of +1,075.00%. The same year closed with a net loss of $68.99M. Trailing earnings per share are −0.55.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $893.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 702.72 times revenue. On price-to-sales that is 52.8 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.8. Annualized volatility over the trailing 5 years is 252.14%. Over the trailing twelve months the total return is −56.36%. Across 5 years the annualized return works out at −31.90%.

Growth & Income

The record shows no dividend for PROK.

Across the complete calendar years on file, 2025 returned +32.54% and 2023 returned −74.05%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −35.71% year to date.

Peer Comparison

ProKidney Corp. (PROK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ProKidney Corp. PROK $574.82M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ProKidney Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Visit website →